MOUNTAIN VIEW, Calif., May 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the upcoming European Congress on Obesity meeting to be held May 25 to May 28, 2011, at the ICEC Lutfi Kirdar Convention & Exhibition Center in Istanbul, Turkey. The details of the presentations are as follows:Oral presentation:Friday, May 27 – Novel Drugs Session, Presentation time 17:15-17:30 (local time)Authors:
Stephan Rossner, MD, PhD; Craig A. Peterson, MS; Barbara Troupin, MD, MBATitle:
CARDIOMETABOLIC RISK REDUCTION IS DIRECTLY RELATED TO MAGNITUDE OF WEIGHT LOSS WITH LOW DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) [T5:RS4.4]Poster presentations:Thursday, May 26– Hot Topic Poster Session, Presentation time 13:00-15:00 (local time)Authors:
George A. Bray, MD; Louis J. Aronne, MD; Alok K. Gupta, MD; Wesley W. Day, PhD; Barbara Troupin, MD, MBATitle:
EFFICACY AND TOLERABILITY OF TOPIRAMATE ALONE AND IN COMBINATION WITH PHENTERMINE [HTP.025]Friday, May 27– Poster Session, Presentation time 13:00-15:00 (local time)Authors:
W. Timothy Garvey, MD; Craig A. Peterson, MS; Barbara Troupin, MD, MBATitle:
WEIGHT LOSS WITH LOW-DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE THERAPY IMPROVES GLYCAEMIC STATUS AND PREVENTS PROGRESSION TO TYPE 2 DIABETES MELLITUS [T5:P.102]Authors:
W. Timothy Garvey, MD; Wesley W. Day, PhD, Charles H. Bowden, MDTitle:
LONG-TERM TREATMENT WITH CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE DEMONSTRATES SUSTAINED WEIGHT LOSS OVER 108 WEEKS [T5:P.103]All posters will be displayed in the Exhibition Hall from the afternoon of May 25th until the morning of May 28th.
About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug c
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved